Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Generic, Biosimilar Society Adopts 2040 Vision for Japan’s Pharma Industry
The Japanese Society of Generic and Biosimilar Medicines has approved its “future vision” for Japan’s pharmaceutical industry through 2040, setting out the goals for four sectors: off-patent medicines, biosimilars, OTC drugs, and APIs. Rather than treating the four sectors separately,…
To read the full story
Related Article
ORGANIZATION
- JPMA to Complete Shift to Legal Entity on October 1
September 30, 2026
- Generic Use Rate Hits Record 90.4% in April-June: JGA
September 30, 2026
- JaDHA Calls for Digital Health Seat in Chuikyo Reform
September 28, 2026
- Digital Health Group Eager to Gain Full Seat at Chuikyo Table
September 25, 2026
- Japan Wholesalers’ Profit Margin Worsens to 1.04% as Costs Rise
September 25, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…